Wishbone SA appears in FDA premarket records as the legal applicant for dental bone grafting materials filed under 21 CFR 872.3930, product code NPM, device class 2. The most recent record is Wishbone HAE, submitted as K260096 and received on 13 January 2026, with a substantially equivalent decision dated 9 October 2026. The filing was a traditional 510(k) reviewed by the dental panel, and the record indicates a summary statement rather than a third-party review. An earlier clearance, K211551 for Wishbone HA, was addressed to the company at Rue de l'Expansion in Flémalle, Belgium. [1][2][4][5]
Wishbone HAE and the K260096 clearance
K260096 covers the device named Wishbone HAE, classified as Bone Grafting Material, Animal Source under regulation 872.3930, device class 2, product code NPM. FDA recorded the application as received on 13 January 2026 and issued a Substantially Equivalent (SESE) decision on 9 October 2026. The clearance type is listed as Traditional, the third-party review flag is No, and the advisory committee is Dental. The applicant contact on the record is Caroline Trus at Rue De L'Expansion 1, Flémalle, Belgium. [1][2][4]
The FDA record notes that a summary is available for this submission, and the review panel is identified as Dental. The device name and regulation number place the filing within the animal-source bone grafting category rather than a synthetic or metallic implant category. [1][4]
Earlier Wishbone HA filing
An FDA letter for K211551 addresses Wishbone SA, care of Operations Manager Emilie Dory, at 1, Rue de l'Expansion, Flémalle, Liege 4400, Belgium. The trade name in that letter is Wishbone HA, with regulation number 21 CFR 872.3930, regulation name Bone Grafting Material, class II, product code NPM. The submission is dated 7 June 2021 and was received 8 June 2021. [5]
The conclusion section of that review states that the information in the 510(k) submission demonstrates the Wishbone HA is substantially equivalent to the predicate. The letter does not identify the predicate device in the available text. [5]
Published product information
Wishbone SA's own users and patients information page refers to Wishbone HA and states that content can vary based on regulatory requirements in the reader's country. The page says updated information on implanted devices will be provided to patients there, and that the Wishbone HA device will be identified with its UDI. The same page references an IFU for clinical investigation CIV-24-01-045555 approved by the FAMHP. [3]
The manufacturer's page also lists W-Bone as a US tradename and describes Wishbone xenograft among its product and distribution links. These are the company's own published labels; the available text does not establish commercial availability, clinical performance or which markets each name covers. [3]
What the filing record shows and does not show
The linked FDA collection for this company contains one 510(k) record, K260096, with a decision count of one Substantially Equivalent decision and no recall records in the sample. That count reflects the filings retrieved as of 20 November 2026, not total company sales, total portfolio or safety performance. [1][4]
The records identify Wishbone SA as the applicant and give a Belgian filing address; they do not establish a headquarters, ownership structure, parent company or brand relationship beyond the applicant name. No cleared indication text, clinical outcome data or post-market results appear in the available sources. [1][4][5]

